[Clinical results of treatment with the UFT fine granule preparation under cooperative study. Tokyo Cancer Chemotherapy Cooperative Study Group].

We have carried out Phase II study by single oral administration of UFT fine granule preparation consisting of 1-(2-tetrahydrofuryl)-5-fluorouracil(FT-207) and uracil in the molar ratio of 1 : 4. There were 40 evaluable cases out of 54 registered cases, and PR rate was 10.0%. We have observed 2 PR cases out of 14 evaluable cases with stomach cancer, and the response rate was 14.3%. There were PR cases in hepatoma and breast cancer also. Myelosuppression appeared in 10.6% and subjective and objective side effects in 27.1%, in which major symptoms were gastrointestinal disorder similar to those observed in the study of UFT Capsule preparation. We did not observe hepatic and renal malfunctions.